Key Highlights

  • Amgen (NASDAQ:AMGN) lifted third-quarter total Revenue 8% to USD 10.4 billion, even though Prolia sales dropped 45% to USD 632 million as lower-cost biosimilar competition arrived.
  • Teva Pharmaceutical (NYSE:TEVA) posted revenue of USD 4,395 million, a 2% decline, yet gross Margin climbed to 55.5% from 51.4% as branded products carried a bigger share of sales.
  • BioNTech (NASDAQ:BNTX) booked EUR 1.3 billion of revenue against EUR 1.5 billion a year earlier, and EUR 613 million of that total came through its BMS collaboration.
  • Ultragenyx (NASDAQ:RARE) agreed to sell two priority review vouchers for USD 413 million combined and plans to trim roughly 20% of its workforce.

Amgen (NASDAQ:AMGN): Newer Medicines Fill the Prolia Gap

Amgen (NASDAQ:AMGN) published its third-quarter 2026 figures on November 3, 2026, showing total revenue up 8% to USD 10.4 billion. Product sales reached USD 9.883 billion, compared with USD 9.137 billion in the prior-year quarter. Volume gains from Repatha, which climbed 37% to USD 1,085 million, along with Imdelltra at USD 406 million (up 128%) and Uplizna at USD 451 million (up 191%), absorbed the blow from older franchises. Prolia slid 45% to USD 632 million and Xgeva fell 47% once biosimilar denosumab copies entered the market, a shift in which cheaper versions of established drugs replace the originals in pricing. Non-GAAP EPS reached USD 6.45, up 14%, while GAAP EPS hit USD 7.08, up 19%. The non-GAAP Operating Margin improved just 0.2 points to 47.3%, so profit growth depends heavily on volume. At September 30, 2026, Amgen (NASDAQ:AMGN) carried USD 54.0 billion of Debt against USD 13.2 billion of cash, and free Cash Flow was USD 3.7 billion versus USD 4.2 billion. Biosimilar pricing, Medicare price-setting under the Inflation Reduction Act and obesity trial data for MariTide remain the main risks.

Teva Pharmaceutical (NYSE:TEVA): Richer Mix Offsets Generic Erosion

Teva Pharmaceutical (NYSE:TEVA) lodged its Quarterly Report for the period ended September 30, 2026 on November 3, 2026. Revenue slipped 2% to USD 4,395 million, as lower U.S. generic sales, most notably for lenalidomide capsules, outweighed gains in branded medicines. U.S. generic revenue fell 39% to USD 718 million, while AUSTEDO grew 21% to USD 727 million and UZEDY climbed 96% to USD 85 million. That shift toward branded products lifted gross margin to 55.5% from 51.4%. Other costs pulled in the opposite direction. Legal settlements and loss contingencies rose to USD 202 million from USD 60 million, and net financial expenses reached USD 414 million compared with USD 237 million. Operating Income landed at USD 714 million versus USD 882 million, and debt stood at USD 16,718 million. Management halted the emrusolmin Phase II study after an interim futility analysis, citing no safety concerns. Teva Pharmaceutical (NYSE:TEVA) also started trading ordinary shares on the New York Stock Exchange on September 14, 2026, in place of ADSs. Interest costs, legal charges and Tariff protections that may not cover future products remain risks.

BioNTech (NASDAQ:BNTX): Collaboration Income Softens a Vaccine Slump

BioNTech (NASDAQ:BNTX) walked investors through its third-quarter 2026 numbers on a call held November 3, 2026. Revenue came in at EUR 1.3 billion, down from EUR 1.5 billion, a drop the company linked mostly to weaker expected Demand for its COVID-19 vaccine. The collaboration with BMS on pumitamig contributed EUR 613 million, so a large share of the quarter reflects Partnership accounting rather than product sales. Management lifted the midpoint of its 2026 revenue guidance, which now sits at EUR 1.7 to 1.9 billion. Adjusted R&D spending increased to EUR 579 million from EUR 479 million, and cash plus securities totaled EUR 16.2 billion. Clinical updates were mixed. In the non-pivotal portion of a squamous lung cancer study, gotistobart delivered median overall survival of 18.5 months, compared with 10 months for docetaxel. A first interim look at the pivotal segment is due before year-end, when an independent committee will decide whether to unblind or keep going. The AHEAD-MERIT study missed its first primary endpoint. Uğur Şahin delivered his final Earnings Call as chief executive, and Guido Oelkers will take over by February 1 at the latest. Early response rates came from small patient groups and may not hold in larger trials.

Ultragenyx (NASDAQ:RARE): Voucher Proceeds Against a Restructuring

Ultragenyx (NASDAQ:RARE) is a biopharmaceutical company concentrating on rare and ultra-rare genetic diseases, and it reported third-quarter results on November 3, 2026. The FDA gave Genglycos Accelerated Approval in August 2026 and Fayuvi full approval in September, and each approval earned a priority review voucher, a transferable certificate that accelerates a future FDA review. The Genglycos voucher sold for USD 210 million and the sale has closed. The Fayuvi voucher agreement, worth USD 203 million, is expected to close later in November, and net proceeds from both sales should land near USD 350 million. Total revenue reached USD 173 million, up from USD 160 million, with Crysvita contributing USD 109 million, and the net loss narrowed to USD 118 million from USD 180 million. The restructuring trims about 20% of headcount to roughly 1,000 people and ends UX701, a Wilson disease program that missed its study goals. Ultragenyx (NASDAQ:RARE) reiterated its target of full-year GAAP profitability in 2027. Possible FDA Withdrawal of the Genglycos accelerated approval if confirmatory studies fail, an unfinished Fayuvi sale and disruption from the Job cuts all count as risks.

Where Things Stand

Mixed readings come from older revenue fading while newer products and cost moves pick up the slack. The 45% Prolia decline at Amgen (NASDAQ:AMGN) is the clearest example of that trade. Teva Pharmaceutical (NYSE:TEVA) exchanged a 2% revenue dip for a higher margin, though legal and interest costs took back part of that gain. BioNTech (NASDAQ:BNTX) leaned on collaboration revenue as vaccine demand eased, and its gotistobart interim analysis arrives before year-end. Ultragenyx (NASDAQ:RARE) holds USD 401 million of cash before voucher proceeds, and its loss rate explains the restructuring. Biosimilar competition, drug pricing rules and trial readouts are shared risks, and no filing guarantees the next quarter. The balance of evidence points to a transition period rather than a clean beat or miss.